In exploring barriers in rare disease research and drug development, experts highlight a lack of robust models, limited trial ...
Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results